Bansal and colleagues describe survival after left ventricular assist device placement for patients with end-stage renal disease (ESRD), based on Medicare claims associated with data in the United States Renal Data System registry. Prognosis for these patients was very poor compared to patients without ESRD, particularly in the short-term.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Mechanical circulatory assistance
December 22, 2017
December 21, 2017
Interesting to read the mortality and renal morbidity of PCI after serious MI. The choice of dual primary outcome may have been an afterhought....
November 16, 2017
The incoming issue of the Journal comes with an interesting group of papers revolving around a provocative topic: work from Seattle on the absence of predictive value of standard pulmonary function tests in LVAD surgery. Vivek Rao takes the opportunity to present his thoughts in this brief editorial, the important central message of which cannot be
November 16, 2017
An enthusiastic yet balanced and succinct editorial on the occasion of a small series with short follow-up and absolute survival of ECMO-supported recipients of pulmonary transplantation (mostly with interstitial fibrosis) with short waiting time after ECMO (less than 16 days).
October 27, 2017
A measured succinct reflection on MagLev and older ventricular assist devices, on the occasion of a relevant 'expert opinion' paper on the topic.
October 12, 2017
Rajamiyer Venkateswaran of the Wythenshawe Hospital in Manchester, UK, asks whether it is possible to predict when a patient undergoing high-risk cardiac surgery will need postoperative mechanical circulatory support. He also discusses his institution's approach to transfering a patient to mechanical circulatory support.
October 12, 2017
The Impella RP device was approved by the FDA for use as a temporary percutaneous assist for the right ventricle, as announced by Abiomed. Use is approved for up to 14 days for a variety of indications including post MI, heart transplant, open heart surgery, or right heart failure after LVAD implant.
October 6, 2017
A stimulating editorial triggered by tri-species autopsy work on angiodysplasia potentially attributable to continuous-flow LVAD. Dr Birks discusses the findings and appears open to the suggestion that LVAD per se is a cause of gastrointestinal angiodysplasia and thence bleeding, as opposed to the anticoagulation for LVAD.
September 19, 2017
The authors queried the UNOS heart transplantation database to determine if LVAD device-related complications (DRCs) were associated with worse postoperative graft survival. The 5 categories of DRCs were as follows: device thrombosis, infection, device malfunction, life-threatening arrhythmias, and others.
June 28, 2017
The authors report on 38 patients who underwent bilateral lung transplantation for severe pulmonary hypertension with routine application of prophylactic postoperative veno-arterial extracorporeal membrane oxygenation (ECMO).